Nature Biotechnology
22, 387 - 391 (2004)
doi:10.1038/nbt0404-387
Making prevention payAlan Dove
Alan Dove is a freelance writer based in New York. Funding for biodefense is spurring new vaccine and anti-infective programs at several biotech companies.
|
